Gilead Projects Full-Year Loss Due to $11.5B Acquisition Charge, Despite Raising Sales Forecast
GILD sits 40% above its 52-week low of $95.295.
Summary
Gilead Sciences reported stronger-than-expected first-quarter earnings and revenue, and raised its 2026 sales forecast by $400 million to a range of $30 billion to $30.4 billion. However, the company drastically cut its full-year 2026 profit outlook, now expecting an adjusted loss of $1.05 to $0.65 per share, a significant reversal from its previous profit estimate of $8.45 to $8.85 per share. This revised guidance is primarily due to an anticipated $11.5 billion charge in the second quarter related to recent acquisitions, including Arcellx, Ouro Medicines, and Tubulis. While the completion of the Arcellx acquisition was recently announced, the magnitude of this non-cash charge and its impact on full-year profitability is new and material information. Traders will focus on the substantial shift to a projected loss, which overshadows the positive Q1 performance and increased sales guidance, likely leading to negative pressure on the stock. Investors will be watching for further details on the integration of these acquisitions and their long-term financial contributions.
At the time of this announcement, GILD was trading at $133.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $166.4B. The 52-week trading range was $95.30 to $157.29. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.